Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
FSD Pharma Inc Class B (HUGE)HUGE
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: HUGE (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -52.05% | Upturn Advisory Performance  1 | Avg. Invested days: 18 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -52.05% | Avg. Invested days: 18 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.07M USD |
Price to earnings Ratio - | 1Y Target Price 2.6 |
Dividends yield (FY) - | Basic EPS (TTM) -16.25 |
Volume (30-day avg) 436382 | Beta 0.85 |
52 Weeks Range 3.50 - 97.50 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 0.07M USD | Price to earnings Ratio - | 1Y Target Price 2.6 |
Dividends yield (FY) - | Basic EPS (TTM) -16.25 | Volume (30-day avg) 436382 | Beta 0.85 |
52 Weeks Range 3.50 - 97.50 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.47% | Return on Equity (TTM) -63.89% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 3600482 | Price to Sales(TTM) 91.86 |
Enterprise Value to Revenue 98.56 | Enterprise Value to EBITDA -1.57 |
Shares Outstanding 708609 | Shares Floating 600696 |
Percent Insiders 9.74 | Percent Institutions 2.69 |
Trailing PE - | Forward PE - | Enterprise Value 3600482 | Price to Sales(TTM) 91.86 |
Enterprise Value to Revenue 98.56 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 708609 | Shares Floating 600696 |
Percent Insiders 9.74 | Percent Institutions 2.69 |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
FSD Pharma Inc Class B is a biopharmaceutical company focused on the research and development of cannabinoid-based treatments. The company was founded in 2014 and is headquartered in Cobourg, Ontario, Canada. FSD Pharma Inc Class B's core business areas include developing and commercializing pharmaceutical-grade cannabis products for various medical conditions.
The company's leadership team includes Dr. Raza Bokhari as the CEO, who has a background in healthcare, pharmaceuticals, and investment banking. The corporate structure of FSD Pharma Inc Class B includes various departments such as research and development, production, and distribution.
Top Products and Market Share:
FSD Pharma Inc Class B's top products include cannabinoid-based medicines for conditions such as chronic pain, epilepsy, and other neurological disorders. The company's products have gained traction in the global market, with a growing presence in the US market as well. FSD Pharma Inc Class B competes with other companies in the medical cannabis and pharmaceutical industries.
Total Addressable Market:
The total addressable market for cannabinoid-based treatments is growing rapidly, with increasing acceptance of medical cannabis for various health conditions. FSD Pharma Inc Class B operates in a market that is expected to expand significantly in the coming years, driven by changing regulations and growing awareness of the potential benefits of cannabinoids.
Financial Performance:
FSD Pharma Inc Class B's recent financial statements show steady revenue growth, improving profit margins, and positive earnings per share (EPS). The company has been able to maintain a healthy balance sheet and generate positive cash flow. Year-over-year financial performance comparisons indicate consistent growth and financial stability.
Dividends and Shareholder Returns:
FSD Pharma Inc Class B does not currently pay dividends, as the company is focused on reinvesting profits into research and development initiatives. Shareholder returns have been positive over the past few years, reflecting the company's growth trajectory and market performance.
Growth Trajectory:
Historically, FSD Pharma Inc Class B has shown strong growth over the past 5 to 10 years, driven by product innovation and strategic partnerships. The company is expected to continue its growth trajectory based on industry trends and market demand for cannabinoid-based treatments.
Market Dynamics:
The industry FSD Pharma Inc Class B operates in is dynamic, with evolving trends, regulatory changes, and technological advancements. The company is well-positioned within the industry, with a focus on innovation and adaptability to market changes.
Competitors:
Key competitors of FSD Pharma Inc Class B include companies such as Canopy Growth Corporation (CGC) and Aurora Cannabis Inc (ACB). FSD Pharma Inc Class B competes with these companies in the medical cannabis and pharmaceutical markets, with a focus on developing differentiated products and building a strong market presence.
Potential Challenges and Opportunities:
Challenges for FSD Pharma Inc Class B include regulatory uncertainties, competition, and supply chain issues. However, the company also has opportunities for expansion into new markets, product developments, and strategic partnerships that can drive future growth and success.
AI-Based Fundamental Rating:
Based on an AI-based rating system, FSD Pharma Inc Class B's stock fundamentals are rated as 8 out of 10. This rating is justified by the company's strong financial health, market position, and future growth prospects, supported by data-driven insights and analysis.
Sources and Disclaimers:
Sources used for this analysis include the company's official website, financial reports, industry publications, and market research data. This information is intended for informational purposes only and should not be used as the sole basis for investment decisions. Investors should conduct their own research and consult with financial advisors before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FSD Pharma Inc Class B
| Exchange | NASDAQ | Headquaters | Toronto, ON, Canada |
| IPO Launch date | 2018-06-08 | Founder, CEO, President & Executive Co-Chairman | Mr. Zeeshan Saeed |
| Sector | Healthcare | Website | https://www.fsdpharma.com |
| Industry | Drug Manufacturers - Specialty & Generic | Full time employees | - |
| Headquaters | Toronto, ON, Canada | ||
| Founder, CEO, President & Executive Co-Chairman | Mr. Zeeshan Saeed | ||
| Website | https://www.fsdpharma.com | ||
| Website | https://www.fsdpharma.com | ||
| Full time employees | - |
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.